Undisclosed In-licensed Program
NASH (Non-alcoholic steatohepatitis)
Phase 2Active
Key Facts
About Viscient Biosciences
Viscient Biosciences is a private, preclinical-stage biotech founded in 2014 that is pioneering a human-centric drug discovery platform. The company utilizes proprietary 3D human tissue models, validated to recapitulate complex diseases like fatty liver disease, combined with genomics and transcriptomics to identify novel disease-driver genes as therapeutic targets. Viscient has advanced one internally discovered drug to the preclinical stage and is in-licensing a second asset for Phase 2 studies, positioning itself to address the multi-billion dollar NASH market. The company is led by Keith Murphy, a seasoned executive and co-founder of the 3D bioprinting firm Organovo.
View full company profileTherapeutic Areas
Other NASH (Non-alcoholic steatohepatitis) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Internal Program | Viscient Biosciences | Preclinical |
| EDL6D | EndoLipiD Therapeutics | Preclinical |
| ALN-HSD | Alnylam Pharmaceuticals | Phase 1 |